Trial Profile
A Phase 1b, Double-Blind, Randomized, Placebo-Controlled Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TT301/MW189 Administered Intravenously to Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Mar 2022
Price :
$35
*
At a glance
- Drugs TT 301 (Primary)
- Indications Alzheimer's disease; CNS disorders; Rheumatoid arthritis
- Focus Adverse reactions; First in man
- 31 Jul 2020 Results assessing safety, pharmacokinetics and pharmacodynamic profiles presented at the Alzheimer's Association International Conference 2020
- 15 May 2020 Status changed from active, no longer recruiting to completed.
- 12 Jun 2019 Status changed from recruiting to active, no longer recruiting.